In a filing, Sarepta Therapeutics Inc revealed its Director Nicaise Claude unloaded Company’s shares for reported $0.25 million on Mar 12 ’25. In the deal valued at $99.64 per share,2,491 shares were sold. As a result of this transaction, Nicaise Claude now holds 27,812 shares worth roughly $1.09 million.
Then, Nicaise Claude bought 2,491 shares, generating $248,226 in total proceeds.
Before that, Wigzell Hans Lennart Rudolf sold 10,500 shares. Sarepta Therapeutics Inc shares valued at $1,310,820 were divested by the Director at a price of $124.84 per share. As a result of the transaction, Wigzell Hans Lennart Rudolf now holds 22,840 shares, worth roughly $0.89 million.
Scotiabank upgraded its Sarepta Therapeutics Inc [SRPT] rating to a Sector outperform from a a Sector perform in a research note published recently. A number of analysts have revised their coverage, including Evercore ISI’s analysts, who decreased its forecast for the stock in early May from “an Outperform” to “an In-line”. Wells Fargo began covering SRPT with “an Overweight” recommendation on April 11, 2025. H.C. Wainwright revised its rating on April 02, 2025. It rated SRPT as “a Neutral” which previously was an “a Sell”.
Price Performance Review of SRPT
On Tuesday, Sarepta Therapeutics Inc [NASDAQ:SRPT] saw its stock fall -1.61% to $39.07. Over the last five days, the stock has gained 0.51%. Sarepta Therapeutics Inc shares have fallen nearly -67.87% since the year began. Nevertheless, the stocks have fallen -66.73% over the past one year.
How much short interest is there in Sarepta Therapeutics Inc?
A steep rise in short interest was recorded in Sarepta Therapeutics Inc stocks on 2025-05-30, growing by 2.56 million shares to a total of 9.26 million shares. Yahoo Finance data shows the prior-month short interest on 2025-04-30 was 6.7 million shares. There was a rise of 27.69%, which implies that there is a positive sentiment for the stock.
